3beta- hydroxy- 17- (1H- benzimidazole- 1- yl)androsta- 5,16- diene

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Belosay, Aashvini: 1 article (08/2008)
2.	Brodie, Angela M H: 1 article (08/2008)
3.	Chopra, Pankaj: 1 article (08/2008)
4.	Fang, Hong-Bin: 1 article (08/2008)
5.	Gediya, Lalji K: 1 article (08/2008)
6.	Guo, Zhiyong: 1 article (08/2008)
7.	Khandelwal, Aakanksha: 1 article (08/2008)
8.	Njar, Vincent C O: 1 article (08/2008)
9.	Schayowitz, Adam: 1 article (08/2008)
10.	Vasaitis, Tadas: 1 article (08/2008)

1.	Prostatic Neoplasms (Prostate Cancer) 08/01/2008 - "Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer." 08/01/2008 - "We previously reported that our novel compound 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (VN/124-1) is a potent 17alpha-hydroxylase/17,20-lyase (CYP17) inhibitor/antiandrogen and strongly inhibits the formation and proliferation of human prostate cancer LAPC4 tumor xenografts in severe combined immunodeficient mice. "
2.	Neoplasms (Cancer) 08/01/2008 - "We previously reported that our novel compound 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (VN/124-1) is a potent 17alpha-hydroxylase/17,20-lyase (CYP17) inhibitor/antiandrogen and strongly inhibits the formation and proliferation of human prostate cancer LAPC4 tumor xenografts in severe combined immunodeficient mice. "

1.	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)
2.	Androgen Receptors (Androgen Receptor)
3.	Mixed Function Oxygenases (Monooxygenases)
4.	Androgen Antagonists (Antiandrogens)